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Background: Screening high-risk individuals with low dose CT decreased lung cancer mortality in the National
Lung Screening Trial (NLST), but the validity of directly extrapolating these results to an Asian population is unclear.
Using statistical models on Surveillance, Epidemiology and End Result (SEER) data, 27 % of lung cancer patients in the
United States were estimated to meet the screening criteria. This study aims to evaluate the performance of the NLST
criteria in Asian lung cancer patients and to examine the characteristics of those who did not meet the criteria.
Methods: We conducted a retrospective study of Asian lung cancer patients treated at Maimonides Cancer Center
between 1/2008 and 6/2013. Data on demographics, smoking history, cancer stage, histology, and EGFR/ALK mutation
status were collected and analyzed.
Results: Of 116 eligible patients, 75 patients (65 %) were smokers which included 26 light smokers (22 %). Thirty-two
patients (27.8 %) met the NLST criteria. Extending the age limit to 79 would cover 8 % more patients while removing
the lower age limit would only cover 2 % more. None of the female patients met the criteria as they were all never or
light smokers. Two-thirds of male patients younger than age 55 were never or light smokers. The EGFR mutation rate
was 67 % in female and 28 % in male patients.
Conclusion: The percentage of Asian patients meeting the NLST criteria is similar to that estimated for the United
States population, suggesting that extension of the criteria to an Asian population is valid. One-third of the patients
were non-smokers and an additional one-fourth were light smokers, comprised mostly of female and young male
patients. Further strategies for screening these individuals based on non-tobacco factors are urgently needed.
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Lung cancer is the most common cancer in the world.
According to the World Health Organization (WHO),
approximately 1.8 million new cases were diagnosed
worldwide in 2012, 58 % of which occurred in Asia and
Africa [1]. While the incidence of lung cancer is decreas-
ing in the United States, it continues to grow in Asia [2].
The 5-year survival rate is only 49 % in stage I, and a
dismal 2 % in stage IV disease [3]. The recently pub-
lished National Lung Screening Trial (NLST) showed a
20 % reduction in lung cancer mortality after three
rounds of annual screening by low dose CT in compari-
son to conventional chest radiography [4]. The entry* Correspondence: yxu@maimonidesmed.org
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smoking at least 30 pack-years and 3) currently smoking
or quit smoking within 15 years. These high-risk criteria
emphasize age and cumulative smoke exposure. Based
on these numbers and the projection of subjects aging
during the screening period in the NLST, the United
States Preventive Services Task Force (USPSTF) recom-
mends screening individuals age 55–80 with similar
smoking exposure [5].
It has been demonstrated that smoking is responsible
for up to 90 % of cases of lung cancer in developed
countries, with the risk increasing with quantity and
duration of smoking [6]. However, the epidemiology of
lung cancer may be different in Asian populations [7].
While the prevalence of smoking [8], air pollution and
environmental hazards [9] are considered to be signifi-
cantly higher in developing countries, up to 30–40 % ofis distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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to only 10 % of patients in the United States [10].
Lung cancer in Asians is also genetically diverse with
up to 35 % of patients harboring epidermal growth fac-
tor receptor (EGFR) mutations in contrast to only 10 %
of Caucasian patients [11, 12]. The EGFR belongs to the
receptor tyrosine kinase (RTK) family. The binding of li-
gands, such as epidermal growth factor, induces a
conformational change that leads to receptor homo- or
heterodimer formation, which results in activation of
EGFR tyrosine kinase activity. Activated EGFR then
phosphorylates its substrates, resulting in activation of
multiple downstream pro-survival pathways involved in
cell proliferation. Approximately 90 % of these muta-
tions are exon 19 deletions or exon 21 L858R point mu-
tations [13]. Another important mutation, the anaplastic
lymphoma kinase (ALK) translocation, is responsible for
approximately 3–5 % of non-small-cell lung cancer
(NSCLC) and is found predominately in adenocarcin-
omas [14]. ALK lung cancer patients are likely to be
younger and never or light smokers. ALK-rearrangements
in NSCLC are, for the most part, not found in EGFR- or
KRAS-mutated tumors [15]. These mutations provide
therapeutic targets for several tyrosine kinase inhibitors.
In the NLST trial, only 2 % of the study population
were Asian, presumably diluting the effect of character-
istics found only in Asian patients [4]. Using statistical
models on data derived from Surveillance, Epidemiology
and End Result (SEER), Pinsky et al. calculated that 27 %
of lung cancer patients in the United States would have
met the criteria for screening [16]. We hypothesized that
fewer existing Asian lung cancer patients would have
met these screening criteria. In this study, we aimed to
evaluate the performance of the NLST criteria on exist-
ing Asian lung cancer patients; we also focused on the
assessment of the characteristics of those not meeting
the criteria.
Methods
We conducted a retrospective chart review of Asian lung
cancer patients diagnosed or treated at Maimonides
Cancer Center in Brooklyn, New York between 1/2008
and 6/2013. The study was reviewed and approved by
the Institutional Review Board (IRB) of Maimonides
Medical Center. The study participants were all adults.
The consents were waived by IRB as it was a retrospect-
ive study. Cases were identified from the electronic med-
ical record and Asian ethnicity was determined after a
multistep process. The Asian patients in the current
study were born in Asia, mostly in China, Pakistan and
Bangladesh, and migrated to United States later in life.
Ethnicity was determined initially by last name. It was
further confirmed by reviewing medical records docu-
mentation. This documentation was done by twoChinese speaking physicians, YH and YX, after inter-
viewing the patients during the original encounter. This
multi-step process ensured that the ethnicity was re-
corded as accurately as possible. We collected data on
demographics, cancer stage at diagnosis, histology, his-
tory of smoking including number of pack years and
time since quitting, and EGFR/ALK mutation status. We
calculated the percentage of patients who would have
been eligible for screening based on the NLST criteria:
1) Age 55–74 years old, 2) History of smoking at least
30 pack-years and 3) Current smokers or quit within
15 years. We then analyzed the characteristics that
would have excluded patients from the screening recom-
mendations. For this study “Never smokers” were de-
fined as people who smoked <100 cigarettes in their life
time. The “light smokers” were defined as people who
smoked ≤ 10 pack-years and those who smoked > 10
pack-years were labeled as “heavy smokers” [24]. These
definitions are similar to those used by other epidemio-
logical studies [30–32].
Statistical analysis
The sample size calculation was performed using SEER
data as a comparison. We hypothesized that among
Asian lung cancer patients, only 10 % would have met
the screening criteria, as compared to 27 % based on
SEER data. Using a 95 % confidence limit of +/- 5 %,
139 patients were required with a precision/absolute
error of 5 % and a type I error of 5 %. After exclusion of
non eligible patients, our actual sample size was 116. It
was low to find any small difference between the two
groups; however, it could have detected a large differ-
ence. In an exploratory analysis, Chi-square testing was
applied to detect a significant difference between the
result in our study and that in the literature.
Results
One hundred fifty-one patients were identified; 35 pa-
tients were excluded due to incomplete information. Of
the 116 patients included in the analysis (Table 1), the
median age was 66 years with a range of 33–92 years.
Seventy-seven patients (67 %) were male and 39 (33 %)
were female. Most patients were diagnosed with
advanced disease: 20 patients (17 %) had stage III disease
and 65 patients (56 %) had stage IV disease. A minority
of patients (29 patients, 25 %) were diagnosed with stage
I and II diseases. The most common histology was
adenocarcinoma in 74 patients (64 %).
All patients were Asian born who immigrated to the
U.S. as adults. One hundred six (91 %) patients were of
Chinese origin and 10 patients (9 %) migrated from the
Indian Subcontinent. Seventy-five patients (65 %) were
smokers (72 male and 3 female), of which, 26 patients
(22 %) were light smokers. The other 41 patients (35 %)
Table 1 Characteristics of the study population
Total patients N = 116 (100 %) Smoking status
Male 77 (66.38 %) Never smokers 41
Female 39 (33.62 %) Male 5
Ethnicity Female 36
Chinese 106 (91.38 %)
Indian subcontinenta 10 (8.62 %)
Age Ever smokers 75
Age range 33–92 years Heavy smokers
Median age 66 years Male 54
Age < 55 years 18 Female 0
Age 55–74 years 69 Light smokers
Age > 74 years 29 Male 18
Female 3
Histology Stages
Adenocarcinoma 74 (63.8 %) Stages I and II 29
Squamous cell 24 (20.7 %) Stages III and IV 85
Small cell 8 (6.9 %) Unknown 2
Other rare variants 10 (8.6 %)
EGFR status ALK mutation status
Positive 24/53 Positive 0/33
Male 8/29 Negative 33/33
Female 16/24
aImmigrants from Pakistan and Bangladesh
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never smokers by gender and age group is depicted in
Fig. 1 and Table 2. Among never smokers, 36 were
female and 5 were male (Table 2). Among 39 female
patients, 36 were never smokers and 3 were light
smokers (Table 2, and Fig. 1).Fig. 1 Distribution of heavy smokers/light smokers/never smokers in differeOn applying the NLST criteria, 32 patients (27.8 %)
would have met the recommended screening criteria
(Table. 2). This represents 48 % of patients in the age
range of 55–74 years. (Table 2). Twenty nine patients
were older than 75 years (25 %); twelve of those patients
were heavy smokers who would have otherwise fit into
the NLST criteria. By extending the upper age limit to
79 years, an additional 9 patients (8 %) would have met
the criteria (Table 2). However, in the group of patients
younger than 55, only 4 out of 18 male patients were
heavy smokers and 3 of them would have otherwise met
the NLST criteria (2 % more) (Table 2). Interestingly, in
this age group, 3 male patients were never smokers and
4 were light smokers. This indicates that lowering the
age limit alone may not significantly increase the
number of cancers detected.
None of the female patients met the screening criteria
based on smoking history: Thirty-six were never
smokers and 3 were light smokers. (Table 2, Fig. 1). An
exploratory analysis was performed to evaluate the in-
crease in cases meeting screening criteria by relaxation
of the age limits as well as the smoking history in this
study, and to compare our results to that extracted from
the study on SEER data [16] as shown in Table 2. By
extending the upper age limit to 79 years, 32.9 % of
Caucasian patients would be covered, and similarly
35.3 % of our patients were covered (p > 0.05). By includ-
ing all ever smokers in the 55–74 age group, 47.9 % U.S.
lung cancer patients would be covered, while only
38.8 % of Asian patients would be covered, this
difference was statistically significant (p = 0.03).
EGFR mutation analysis was available for 53 patients,
24 were positive for exon 19 or exon 21 mutations
(Fig. 2). The EGFR-mutated cancers were seen in 16 out
of 24 tested female patients (67 %), all light or nevernt age group
Table 2 Comparison of patients meeting NLST criteria between US population and Asians
Age groups 55–74 years 55–79 years 55–74 years
Smoking status 30 + pack-years current or quit < 15 years 30 + pack-years current or quit < 15 years Ever smokers
Native U.S. populationa 26.7 % 32.9 % 47.9 %
Asians 27.8 % 35.3 % 38.8 %
P value >0.05 > 0.05 0.03
aEstimated by Pinsky et al. on data derived from SEER and US census [16]
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tested male patients (28 %) and 6 were light or never
smokers while 2 were heavy smokers who actually met
the NLST screening criteria (Table 1). The distribution
of EGFR positive cases in the three age groups according
to gender and smoking history is depicted in Fig. 2. The
EGFR mutation positive cases distributed evenly in all
three age groups in both male and female patients
(Fig. 2). Thirty three patients were tested for ALK trans-
location but none was positive for this mutation.
Discussion
The NLST criteria were established after study of a gen-
eral U.S. population; however, direct extrapolation to
Asian patients warrants further consideration. The epi-
demiology of lung cancer in Asian populations is differ-
ent, including more smokers [17] in the community
leading to greater second hand smoking exposure as well
as other environmental hazards [18, 19]. In addition, a
higher percentage of EGFR-mutated cancers are ob-
served in Asians patients than in the general U.S. popu-
lation [20], which correlates with the higher percentage
of never smokers among lung cancer patients in AsianFig. 2 Distribution of EGFR mutations in different age groupscountries. It is imperative to develop screening criteria
that take into account the heterogeneous risk factors in
Asian populations.
In our retrospective study of already diagnosed Asian
lung cancer patients, 27.8 % would have met the NLST
criteria for screening. The result rejected our hypothesis
and revealed that there is no large difference in the rate
of meeting the screening criteria between Asian lung
cancer patients and that of the U.S. population as esti-
mated in the study published by Pinsky et al. [16] In that
study, calculations were based upon statistical models
using data derived from SEER, the U.S. Census and the
National Health Interview Survey, and found that in the
United States 27 % of lung cancer patients would have
met the criteria for screening [16]. In the present
study, our data suggest that the performance of the
NLST criteria to detect lung cancers in an Asian
population is similar to the general U.S. population. It
also implies that the proportion of lung cancer attrib-
utable to heavy smoking in patients aged 55–74 years
is extremely similar in the Asian and general U.S.
populations. Smoking is still the strongest risk factor
for lung cancer in Asian populations.
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factor for lung cancer, then broadening the smoking eli-
gibility should detect more lung cancer patients. The
study by Pinsky et al. [16] suggested that broadening the
current criteria to ever smokers in the 55–74 age range
would cover 47.9 % of patients. However this modifica-
tion may help only marginally to boost the coverage rate
in Asian patients as only 37 % of the patients in our
study would fulfill these criteria. This difference was sta-
tistically significant. In addition, while the coverage
could increase by 8 % if the upper age limit was in-
creased, reducing the lower age limit would only mar-
ginally increase coverage by 2 %. The smoking behavior
in patients younger than age 55 revealed in this study
merits further attention. Two thirds of the male patients
and all of the female patients in this group were never
or light smokers. Carcinogens other than tobacco are
likely to be the driving force and require further study.
Furthermore, 35 % of our patients were never smokers
and all of our female patients were never smokers or
light smokers. This data is consistent with previous re-
ports [22]. It is quite different from studies in the U.S.
where smoking accounts for up to 90 % of lung cancers
and only 19 % of female lung cancer patients report no
smoking history [21]. Overall, our study has highlighted
an important difference in the percentage of Asian lung
cancer patients who are never smokers or light smokers.
Relaxing the stringent smoking history in the NLST cri-
teria will still not help this cohort.
The development of screening criteria for never or light
smokers is a great challenge. In view of the vast number
of patients with lung cancer in Asia, 30–40 % of whom
are never smokers, this is a serious problem [23]. Theoret-
ically, the risk factors in this group could be environmen-
tal hazards, the development of driver mutations in the
EGFR or other genes, or an interaction between the two.
There is a high EGFR mutation rate in both male and fe-
male patients in this study, consistent with that reported
in previous studies of Asian patients [24]. This holds
promise as potential screening marker in never/light
smokers in the future. There has been persistent interest
in detecting molecular signatures in the sputum [25],
bronchial alveolar lavage and peripheral blood [26] of lung
cancer patients, albeit with little success. Those studies
utilized FISH for EGFR mutations [27], micro RNA [28]
and specific gene methylation markers [29]. Besides being
non-invasive, assays for EGFR mutation analysis should be
at least as sensitive but more specific than low dose CT to
minimize the risk of false positive results, a major short-
coming of CT screening in the NLST trial. In an encour-
aging small study testing this model, the sensitivity of
EGFR mutation detection in the sputum using various
techniques varied from 30–50 %, with very high specificity
of up to 100 % [25].To our knowledge, this is the first study to evaluate
the performance of the NLST criteria in Asian patients.
The strength of this study is the detailed analysis of an
array of factors including smoking history, duration, age,
EGFR status, etc. in a unique population who are of
Asian descent. The limitations of this study are the small
sample size which would not allow detection of a small
difference if it existed. In addition, this is a retrospective
study, so patients whose smoking history was incom-
pletely documented were excluded. The other drawback
is the lack of information on the length of time residing
in the U.S., a variable that could affect hazardous expo-
sures. Finding a similar percentage of Asian patients
with lung cancer who met the criteria suggests that
Asian patients may derive a survival benefit from screen-
ing similar to that of the general U.S. population studied
in the NLST. It is important to have a randomized
clinical trial dedicated to Asian lung cancer patients to
confirm such a benefit.
Conclusion
The percentage of Asian patients with lung cancer who
would have met the NLST screening criteria was not
largely different from that estimated for the general U.S.
population. The NLST criteria which emphasize tobacco
exposure are valid for Asian patients. One third of Asian
lung cancer patients are never or light smokers and con-
sist mainly of female patients and those below the age of
55. Further studies are needed to identify additional risk
factors beyond smoking alone to construct a more com-
prehensive screening model for the early diagnosis of
lung cancer in Asian populations.
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